Sartaj Jhooty, Paul Barkhaus, Andrew Brown, Javier Mascias Cadavid, Gregory T Carter, Jesse Crayle, Terry Heiman-Patterson, Xiaoyan Li, Elise Mallon, Christopher Mcdermott, Tasnim Mushannen, Gary Pattee, Dylan Ratner, Paul Wicks, Martina Wiedau, Richard Bedlack
{"title":"ALSUntangled #74：Withania Somnifera (Ashwagandha).","authors":"Sartaj Jhooty, Paul Barkhaus, Andrew Brown, Javier Mascias Cadavid, Gregory T Carter, Jesse Crayle, Terry Heiman-Patterson, Xiaoyan Li, Elise Mallon, Christopher Mcdermott, Tasnim Mushannen, Gary Pattee, Dylan Ratner, Paul Wicks, Martina Wiedau, Richard Bedlack","doi":"10.1080/21678421.2024.2311721","DOIUrl":null,"url":null,"abstract":"<p><p>ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS (PALS) who ask about them. Here, we review withania somnifera (WS) commonly known as ashwagandha or winter cherry. WS has plausible mechanisms for slowing ALS progression because of its effects on inflammation, oxidative stress, autophagy, mitochondrial function, and apoptosis. Preclinical trials demonstrate that WS slows disease progression in multiple different animal models of ALS. Of the five individuals we found who described using WS for their ALS, two individuals reported moderate benefit while none reported experiencing any significant side effects. There is currently one clinical trial using WS to treat PALS; the results are not yet published. There are no serious side effects associated with WS and the associated cost of this treatment is low. Based on the above information, WS appears to us to be a good candidate for future ALS trials.</p>","PeriodicalId":72184,"journal":{"name":"Amyotrophic lateral sclerosis & frontotemporal degeneration","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ALSUntangled #74: Withania Somnifera (Ashwagandha).\",\"authors\":\"Sartaj Jhooty, Paul Barkhaus, Andrew Brown, Javier Mascias Cadavid, Gregory T Carter, Jesse Crayle, Terry Heiman-Patterson, Xiaoyan Li, Elise Mallon, Christopher Mcdermott, Tasnim Mushannen, Gary Pattee, Dylan Ratner, Paul Wicks, Martina Wiedau, Richard Bedlack\",\"doi\":\"10.1080/21678421.2024.2311721\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS (PALS) who ask about them. Here, we review withania somnifera (WS) commonly known as ashwagandha or winter cherry. WS has plausible mechanisms for slowing ALS progression because of its effects on inflammation, oxidative stress, autophagy, mitochondrial function, and apoptosis. Preclinical trials demonstrate that WS slows disease progression in multiple different animal models of ALS. Of the five individuals we found who described using WS for their ALS, two individuals reported moderate benefit while none reported experiencing any significant side effects. There is currently one clinical trial using WS to treat PALS; the results are not yet published. There are no serious side effects associated with WS and the associated cost of this treatment is low. Based on the above information, WS appears to us to be a good candidate for future ALS trials.</p>\",\"PeriodicalId\":72184,\"journal\":{\"name\":\"Amyotrophic lateral sclerosis & frontotemporal degeneration\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Amyotrophic lateral sclerosis & frontotemporal degeneration\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21678421.2024.2311721\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic lateral sclerosis & frontotemporal degeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21678421.2024.2311721","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
ALSUntangled 代表 ALS 患者 (PALS) 对询问的替代治疗和标签外治疗进行审查。在此，我们对俗称灰树花或冬樱桃的睡茄（WS）进行了评述。由于 WS 对炎症、氧化应激、自噬、线粒体功能和细胞凋亡有影响，因此它在延缓 ALS 病程进展方面具有可信的机制。临床前试验证明，在多种不同的 ALS 动物模型中，WS 都能延缓疾病的进展。在我们找到的五位自述使用 WS 治疗 ALS 的患者中，有两人表示获得了中等程度的治疗效果，没有人表示出现任何明显的副作用。目前有一项使用 WS 治疗 PALS 的临床试验，结果尚未公布。WS 没有严重的副作用，治疗成本也很低。根据上述信息，我们认为 WS 是未来 ALS 试验的理想候选药物。
ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS (PALS) who ask about them. Here, we review withania somnifera (WS) commonly known as ashwagandha or winter cherry. WS has plausible mechanisms for slowing ALS progression because of its effects on inflammation, oxidative stress, autophagy, mitochondrial function, and apoptosis. Preclinical trials demonstrate that WS slows disease progression in multiple different animal models of ALS. Of the five individuals we found who described using WS for their ALS, two individuals reported moderate benefit while none reported experiencing any significant side effects. There is currently one clinical trial using WS to treat PALS; the results are not yet published. There are no serious side effects associated with WS and the associated cost of this treatment is low. Based on the above information, WS appears to us to be a good candidate for future ALS trials.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
